BioElectronics Corp. has received over-the-counter use market clearance from the FDA for ActiPatch for the adjunctive treatment of musculoskeletal pain related to plantar fasciitis of the heel and osteoarthritis of the knee.
BioElectronics is an electroceutical company that develops wearable neuromodulation devices to safely mitigate neurologic diseases and improve quality of life. Its shortwave therapy technology uses low-power, pulsed electromagnetic fields to regulate electrical activity of the nervous system.
According to BioElectronics, ActiPatch is a drug-free, wearable nonprescription medical device that provides 720 hours (90, eight-hour treatments) of on/off therapy. Most users obtain relief with only eight hours per day of use, and the device generally lasts several months, depending on use, according to the company. ActiPatch is described by BioElectronics as “an adjunctive or alternative therapy to pain killers, including narcotics.”